Patent 9233974 was granted and assigned to Gilead Sciences on January, 2016 by the United States Patent and Trademark Office.
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.